

ilium Meloxicam 40 Anti-Inflammatory Injection **Troy Laboratories Pty Ltd**

Chemwatch: 5494-68 Version No: 2.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Issue Date: 01/10/2021 Print Date: 05/10/2021 S.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	ilium Meloxicam 40 Anti-Inflammatory Injection	
Chemical Name	Not Applicable	
Synonyms	Not Available	
Chemical formula	Not Applicable	
Other means of identification	Not Available	

Relevant identified uses of the substance or mixture and uses advised against

	A non-steroidal anti-inflammatory, analgesic and antipyretic for use in cattle.	
Relevant identified uses	SDS are intended for use in the workplace. For domestic-use products, refer to consumer labels.	
	Use according to manufacturer's directions.	

Details of the supplier of the safety data sheet

Registered company name	Troy Laboratories Pty Ltd	
Address	7 Glendenning Road Glendenning NSW 2761 Australia	
Telephone	8808 3600	
Fax	02 9677 9300	
Website	www.Troylab.com.au	
Email	admin@troylab.com.au	

Emergency telephone number

Association / Organisation	Troy Laboratories Pty Ltd	
Emergency telephone numbers	02 8808 3600 (Office hours (8am – 4pm, Monday to Friday))	
Other emergency telephone numbers	Not Available	

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	S4	
Classification [1]	Serious Eye Damage/Eye Irritation Category 2A, Reproductive Toxicity Category 2	
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI	

Label elements

Hazard pictogram(s)





Signal word

Warning

Hazard statement(s)

AUH018	In use, may form flammable/explosive vapour/air mixture.	
H319	Causes serious eye irritation.	
H361d	Suspected of damaging the unborn child.	

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P280	Wear protective gloves, protective clothing, eye protection and face protection.

Chemwatch: **5494-68** Page **2** of **11**

Version No: 2.1

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: **01/10/2021**Print Date: **05/10/2021**

P264

Wash all exposed external body areas thoroughly after handling.

Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.	
P305+P351+P338	FIN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.	
P337+P313	If eye irritation persists: Get medical advice/attention.	

Precautionary statement(s) Storage

P405 Store locked up.

Precautionary statement(s) Disposal

P501

Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
64-17-5	10-<20	ethanol
9003-11-6	<10	polypropylene/ polyethylene glycol copolymer
71125-38-7	<5	meloxicam
Not Available	balance	Ingredients determined not to be hazardous
Not Available		includes
7732-18-5	>60	water
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	 If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. 		
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.		
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor. 		
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice. 		

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

for non-steroidal anti-inflammatories (NSAIDs)

- Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.
- Patients should be managed by symptomatic and supportive care following a NSAIDs overdose.
- There are no specific antidotes.
- Emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 g/kg in children), and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose (5 to 10 times the usual dose).
- Forced diuresis, alkalinisation of urine, hemodialysis, or haemoperfusion may not be useful due to high protein binding.
- For gastrointestinal haemorrhage, monitor stool guaiac and administer antacids or sucralfate.
- For mild/moderate allergic reactions, administer antihistamines with or without inhaled beta agonists, corticosteroids, or epinephrine.
- For severe allergic reactions, administer oxygen, antihistamines, epinephrine, or corticosteroids. Nephritis or nephrotic syndrome, thrombocytopenia, or haemolytic anemia may respond to glucocorticoid administration.
- For severe acidosis, administer sodium bicarbonate.
- Administer as required: plasma volume expanders for severe hypotension; diazepam or other benzodiazepine for convulsions; vitamin K1 for hypoprothrombinaemia; and/or dopamine plus dobutamine intravenously to prevent or reverse early indications of renal failure.

Serious gastrointestinal toxicity, such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID

Chemwatch: **5494-68** Page **3** of **11**

Version No: 2.1

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: **01/10/2021**Print Date: **05/10/2021**

therapy. Although minor upper gastrointestinal problems, such as dyspepsia, are common, usually developing early in therapy, physicians should remain alert for ulceration and bleeding in patients treated chronically with NSAIDs even in the absence of previous GI tract symptoms. In patients observed in clinical trials of several months to two years duration, symptomatic upper GI ulcers, gross bleeding or perforation appear to occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and what steps to take if they occur.

Studies to date have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Except for a prior history of serious GI events and other risk factors known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors (e.g., age, sex) have been associated with increased risk. Elderly or debilitated patients seem to tolerate ulceration or bleeding less well than other individuals, and most spontaneous reports of fatal GI events are in this population. Studies to date are inconclusive concerning the relative risk of various NSAIDs in causing such reactions. High doses of any NSAID probably carry a greater risk of these reactions, although controlled clinical trials showing this do not exist in most cases. In considering the use of relatively large doses (within the recommended dosage range), sufficient benefit should be anticipated to offset the potential increased risk of GI toxicity.

SECTION 5 Firefighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances.

- foam.
- dry chemical powder.
- carbon dioxide.

Special hazards arising from the substrate or mixture

pecial nazaros ansing from the substrate of mixture			
Fire Incompatibility	None known.		
Advice for firefighters			
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by any means available, spillage from entering drains or water course. Use water delivered as a fine spray to control fire and cool adjacent area. Avoid spraying water onto liquid pools. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. 		
Fire/Explosion Hazard	WARNING: In use may form flammable/ explosive vapour-air mixtures. The emulsion is not combustible under normal conditions. However, it will break down under fire conditions and the hydrocarbon component will burn. • Combustible. • Slight fire hazard when exposed to heat or flame. • Heating may cause expansion or decomposition leading to violent rupture of containers. • On combustion, may emit toxic fumes of carbon monoxide (CO). • May emit acrid smoke. • Mists containing combustible materials may be explosive. Combustion products include: carbon dioxide (CO2) other pyrolysis products typical of burning organic material. May emit poisonous fumes. May emit corrosive fumes.		
HAZCHEM	Not Applicable		

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for conta	 Remove all ignition sources. Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal.
Major Spills	 Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by all means available, spillage from entering drains or water courses. Consider evacuation (or protect in place). No smoking, naked lights or ignition sources. Increase ventilation. Stop leak if safe to do so. Water spray or fog may be used to disperse / absorb vapour. Contain or absorb spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains.

Chemwatch: **5494-68** Page **4** of **11**

Version No: 2.1

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: **01/10/2021**Print Date: **05/10/2021**

- After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
- If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling ▶ DO NOT allow clothing wet with material to stay in contact with skin Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. DO NOT allow material to contact humans, exposed food or food utensils. Avoid contact with incompatible materials. Safe handling When handling, DO NOT eat, drink or smoke Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Launder contaminated clothing before re-use. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained. Store in original containers. Keep containers securely sealed. No smoking, naked lights or ignition sources. Other information Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Conditions for sale storage, in	cluding any incompatibilities
Suitable container	Glass vials (50mL, 100mL). Packaging as recommended by manufacturer. Check that containers are clearly labelled. Tamper-proof containers. Polyethylene or polypropylene containers. Metal drum with sealed plastic liner. Glass container is suitable for laboratory quantities Polyethylene or polypropylene container. Packing as recommended by manufacturer. Check all containers are clearly labelled and free from leaks.
Storage incompatibility	 Avoid reaction with oxidising agents, bases and strong reducing agents. Avoid strong acids, acid chlorides, acid anhydrides and chloroformates.

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	ethanol	Ethyl alcohol	1000 ppm / 1880 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
ethanol	Not Available	Not Available	15000* ppm
polypropylene/ polyethylene glycol copolymer	6.9 mg/m3	76 mg/m3	460 mg/m3

Ingredient	Original IDLH	Revised IDLH
ethanol	3,300 ppm	Not Available
polypropylene/ polyethylene glycol copolymer	Not Available	Not Available
meloxicam	Not Available	Not Available
water	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
meloxicam	E	≤ 0.01 mg/m³
Notes:	Occupational exposure banding is a process of assigning chemicals into s adverse health outcomes associated with exposure. The output of this pro range of exposure concentrations that are expected to protect worker hea	ocess is an occupational exposure band (OEB), which corresponds to a

Chemwatch: 5494-68 Page 5 of 11

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: 01/10/2021 Print Date: 05/10/2021

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are:

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.

Employers may need to use multiple types of controls to prevent employee overexposure.

- Employees exposed to confirmed human carcinogens should be authorized to do so by the employer, and work in a regulated area.
- Work should be undertaken in an isolated system such as a "glove-box". Employees should wash their hands and arms upon completion of the assigned task and before engaging in other activities not associated with the isolated system.
- Within regulated areas, the carcinogen should be stored in sealed containers, or enclosed in a closed system, including piping systems, with any sample ports or openings closed while the carcinogens are contained within.
- Open-vessel systems are prohibited.
- Each operation should be provided with continuous local exhaust ventilation so that air movement is always from ordinary work areas to the operation.
- Exhaust air should not be discharged to regulated areas, non-regulated areas or the external environment unless decontaminated. Clean make-up air should be introduced in sufficient volume to maintain correct operation of the local exhaust system.
- For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood. Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood.
- Except for outdoor systems, regulated areas should be maintained under negative pressure (with respect to non-regulated areas).
- Local exhaust ventilation requires make-up air be supplied in equal volumes to replaced air.
- Laboratory hoods must be designed and maintained so as to draw air inward at an average linear face velocity of 0.76 m/sec with a minimum of 0.64 m/sec. Design and construction of the fume hood requires that insertion of any portion of the employees body, other than hands and arms, be disallowed.

Personal protection

Appropriate engineering

controls

Version No: 2.1











When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.

Eye and face protection

Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Skin protection

See Hand protection below

NOTE:

- The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374. AS/NZS 2161.10.1 or national equivalent) is recommended
- Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.
 - Contaminated gloves should be replaced.

As defined in ASTM F-739-96 in any application, gloves are rated as:

- Excellent when breakthrough time > 480 min
- Good when breakthrough time > 20 min
- Fair when breakthrough time < 20 min
- Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task

Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.

Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed

Continued...

Hands/feet protection

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: **01/10/2021**Print Date: **05/10/2021**

moisturiser is recommended Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference. Double gloving should be considered. PVC gloves ▶ Change gloves frequently and when contaminated, punctured or torn. Wash hands immediately after removing gloves. ▶ Protective shoe covers. [AS/NZS 2210] ► Head covering. **Body protection** See Other protection below For quantities up to 500 grams a laboratory coat may be suitable. For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers. Other protection For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection. ► Eye wash unit. Ensure there is ready access to an emergency shower. ▶ For Emergencies: Vinyl suit

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

ilium Meloxicam 40 Anti-Inflammatory Injection

Material	СРІ
BUTYL	A
NEOPRENE	A
NATURAL RUBBER	С
NATURAL+NEOPRENE	С
NITRILE	С
NITRILE+PVC	С
PE/EVAL/PE	С
PVA	С
PVC	С
VITON	С

^{*} CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

 $\mbox{\bf NOTE}.$ As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 5 x ES	Air-line*	A-2	A-PAPR-2 ^
up to 10 x ES	-	A-3	-
10+ x ES	-	Air-line**	-

* - Continuous Flow; ** - Continuous-flow or positive pressure demand

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Clear yellow solution; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	1.018
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	7.5-9.1	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (%)	Not Available

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: 01/10/2021 Print Date: 05/10/2021

Not Available Vapour density (Air = 1) VOC g/L Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

Information	on tox	icolog	gical	effects
-------------	--------	--------	-------	---------

producto		
SECTION 11 Toxicological in	nformation	
Information on toxicological et	fects	
Inhaled	co-ordination, and vertig Inhalation of vapours or of the individual.	ay cause drowsiness and dizziness. This may be accompanied by sleepiness, reduced alertness, loss of reflexes, lack of jo. aerosols (mists, fumes), generated by the material during the course of normal handling, may be damaging to the health at the most common signs of inhalation overdose is inco-ordination and drowsiness.
	Ingestion of ethanol (eth Effects on the body:	he material may be damaging to the health of the individual. yl alcohol, "alcohol") may produce nausea, vomiting, bleeding from the digestive tract, abdominal pain, and diarrhoea.
	Blood concentration	Effects Mild-impoined vision, as ardirection and
	<1.5 g/L	Mild: impaired vision, co-ordination and reaction time; emotional instability
Ingestion	1.5-3.0 g/L	Moderate: Slurred speech, confusion, inco-ordination, emotional instability, disturbances in perception and senses, possible blackouts, and impaired objective performance in standardized tests. Possible double vision, flushing, fast heart rate, sweating and incontinence. Slow breathing may occur rarely and fast breathing may develop in cases of metabolic acidosis, low blood sugar and low blood potassium. Central nervous system depression may progress to coma.
	3-5 g/L	Severe: cold clammy skin, low body temperature and low blood pressure. Atrial fibrillation and heart block have been reported. Depression of breathing may occur, respiratory failure may follow serious poisoning, choking on vomit may result in lung inflammation and swelling. Convulsions due to severe low blood sugar may also occur. Acute liver inflammation may develop.
		nmatory drug (NSAID) overdose may produce nausea, vomiting, indigestion and upper abdominal pain. Other effects may ciness, confusion, disorientation, lethargy, "pins and needles", intense headache, blurred vision, ringing in the ears, Isions, stupor and coma.
Skin Contact	There is some evidence Open cuts, abraded or in Entry into the blood-stre	y cause skin cracking, flaking or drying following normal handling and use. to suggest that this material can cause inflammation of the skin on contact in some persons. rritated skin should not be exposed to this material am, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin aterial and ensure that any external damage is suitably protected.

prior to the use of the material and ensure that any external damage is suitably protected.

Direct contact of the eye with ethanol (alcohol) may cause an immediate stinging and burning sensation, with reflex closure of the lid, and a

temporary, tearing injury to the cornea together with redness of the conjunctiva. Discomfort may last 2 days but usually the injury heals without

Eve

There is sufficient evidence to suggest that this material directly causes cancer in humans. Ample evidence exists that this material directly causes reduced fertility

This material can cause eye irritation and damage in some persons.

Ample evidence exists that developmental disorders are directly caused by human exposure to the material.

Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure. There is limited evidence that, skin contact with this product is more likely to cause a sensitisation reaction in some persons compared to the Chronic general population.

Prolonged use of non-steroidal analgesics damages the lining of the gastrointestinal tract, causing ulcers and bleeding. There may be diarrhoea or constipation, perforations causing serious infection, and blood in the vomit or stools.

Prolonged exposure to ethanol may cause damage to the liver and cause scarring. It may also worsen damage caused by other agents.

Prolonged or repeated skin contact may cause degreasing, followed by drying, cracking and skin inflammation.

ilium Meloxicam 40 **Anti-Inflammatory Injection**

TOXICITY IRRITATION

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: 01/10/2021 Print Date: 05/10/2021

	Not Available	Not Available	
	Notividado		
	TOXICITY	IRRITATION	
	Dermal (rabbit) LD50: 17100 mg/kg ^[1]	Eye (rabbit): 500	mg SEVERE
	Inhalation(Mouse) LC50; 39 mg/l4h ^[2]	Eye (rabbit):100	mg/24hr-moderate
ethanol	Oral(Rat) LD50; >7692 mg/kg ^[1]	Eye: adverse eff	ect observed (irritating) ^[1]
		Skin (rabbit):20	mg/24hr-moderate
		Skin (rabbit):400	mg (open)-mild
		Skin: no adverse	e effect observed (not irritating) ^[1]
	TOXICITY	IRRITATION	
polypropylene/ polyethylene glycol copolymer	Inhalation(Rat) LC50; 0.32 mg/L4h ^[2]	Eye (rabbit): 500) mg/24h - mild
grycor coporymer	Oral(Rat) LD50; 2300 mg/kg ^[2]	Skin (rabbit): 50	0 mg/24h - mild
	тохісіту	IRRITATION	
meloxicam	Oral(Rabbit) LD50; 320 mg/kg ^[2]	Eye (rabbit): Not	irritating *
		Skin (rabbit) : No	ot irritating *
	TOXICITY	IRRITATION	
water	Oral(Rat) LD50; >90000 mg/kg ^[2]	Not Available	
Legend: POLYPROPYLENE/	Value obtained from Europe ECHA Registered Subs specified data extracted from RTECS - Register of Tox Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products.	ic Effect of chemical Substances	
-	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet	ic Effect of chemical Substances thylene glycols) are highly susceptible d surfactant is non-sensitizing, many	e to being oxidized in the air. They then form compler of the oxidation products are sensitisers. The
POLYPROPYLENE/ POLYETHYLENE GLYCOL	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many discontact causing inflammation. Replayed so was observed in rats given oral doses ody surface area conversion) for 10-noted above) for 99 weeks. Reprodu fyday, respectively (4.9-fold and 2.5-fold 1 mg/kg/day (0.5-fold the human diduring early embryonic development of the heart, a rare event, at an area conversion) and embryolethality gnoted above) throughout organogenesis. Meloxicam was not dray throughout organogenesis. Meloxicam was not Mutagenicity: Meloxicam was not Mutagenicity: Meloxicam was not	e to being oxidized in the air. They then form complete of the oxidation products are sensitisers. The eated or prolonged exposure to irritants may product as up to 0.8 mg/kg/day (approximately 0.4-fold the weeks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dos at oral doses >/= 5 mg/kg/day (5.4-fold the human is not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam v human dose at 15 mg/day for a 50 kg adult based on b mg/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg increased incidence of embryolethality at oral doses >/ dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal de at 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throu mg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many d contact causing inflammation. Repuras observed in rats given oral doses ody surface area conversion) for 104 noted above) for 99 weeks. Reproduct of the heart, a rare event, at an expression of the heart, a rare event, at an expression of the heart, a rare event, at an expression of the heart, a rare event, at an expression of the heart, and the did during early embryonic developm fect of the heart, a rare event, at an expression and embryolethality aghout organogenesis. Meloxicam we noted above) throughout organogenesis. Meloxicam was not s and an in vivo micronucleus test in	e to being oxidized in the air. They then form complete of the oxidation products are sensitisers. The eated or prolonged exposure to irritants may product a up to 0.8 mg/kg/day (approximately 0.4-fold the weeks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dos at oral doses >= 5 mg/kg/day (5.4-fold the human is not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER MELOXICAM	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam whuman dose at 15 mg/day for a 50 kg adult based on bmg/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg increased incidence of embryolethality at oral doses >/dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal de at 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throumg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome chromosome aberration assay with human lymphocyte	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many d contact causing inflammation. Repuras observed in rats given oral doses ody surface area conversion) for 104 noted above) for 99 weeks. Reproducted above) for 99 weeks. Reproducted above) for 99 weeks. Reproducted above in the first of the human did during early embryonic developmentation of the heart, a rare event, at an earea conversion) and embryolethality aghout organogenesis. Meloxicam was noted above) throughout organogenesis. Meloxicam was not is and an in vivo micronucleus test in ature search.	e to being oxidized in the air. They then form complete of the oxidation products are sensitisers. The eated or prolonged exposure to irritants may product as up to 0.8 mg/kg/day (approximately 0.4-fold the deveks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dose at oral doses >/= 5 mg/kg/day (5.4-fold the human is not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a mouse bone marrow. * Apotex SDS
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER MELOXICAM WATER ETHANOL & POLYPROPYLENE/ POLYETHYLENE GLYCOL	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam whuman dose at 15 mg/day for a 50 kg adult based on bmg/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg increased incidence of embryolethality at oral doses >/ dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal de at 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throu mg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome chromosome aberration assay with human lymphocyte. No significant acute toxicological data identified in literal.	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many d contact causing inflammation. Repuras observed in rats given oral doses ody surface area conversion) for 104 noted above) for 99 weeks. Reproducted above) for 99 weeks. Reproducted above) for 99 weeks. Reproducted above in the first of the human did during early embryonic developmentation of the heart, a rare event, at an earea conversion) and embryolethality aghout organogenesis. Meloxicam was noted above) throughout organogenesis. Meloxicam was not is and an in vivo micronucleus test in ature search.	e to being oxidized in the air. They then form complete of the oxidation products are sensitisers. The eated or prolonged exposure to irritants may product as up to 0.8 mg/kg/day (approximately 0.4-fold the deveks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dose at oral doses >/= 5 mg/kg/day (5.4-fold the human is not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a mouse bone marrow. * Apotex SDS
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER MELOXICAM WATER ETHANOL & POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam whuman dose at 15 mg/day for a 50 kg adult based on bing/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg increased incidence of embryolethality at oral doses >/dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal deat 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throumg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome chromosome aberration assay with human lymphocyte. No significant acute toxicological data identified in literal through the studies in pregnant wome chromosome aberration assay with human lymphocyte.	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many d contact causing inflammation. Repowas observed in rats given oral doses ody surface area conversion) for 104 noted above) for 99 weeks. Reproduj/day, respectively (4.9-fold and 2.5-fe=1 mg/kg/day (0.5-fold the human dnd during early embryonic developmiect of the heart, a rare event, at an area conversion) and embryolethality ighout organogenesis. Meloxicam wanoted above) throughout organogenesis. Meloxicam was not sand an in vivo micronucleus test in ature search.	e to being oxidized in the air. They then form completed of the oxidation products are sensitisers. The seated or prolonged exposure to irritants may product to up to 0.8 mg/kg/day (approximately 0.4-fold the weeks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dose at oral doses >/= 5 mg/kg/day (5.4-fold the human as not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a mouse bone marrow. * Apotex SDS
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER MELOXICAM WATER ETHANOL & POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER Acute Toxicity Skin Irritation/Corrosion	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam v human dose at 15 mg/day for a 50 kg adult based on b mg/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg/increased incidence of embryolethality at oral doses >/ dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal de at 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throu mg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome chromosome aberration assay with human lymphocyte No significant acute toxicological data identified in literal through the material may cause skin irritation after prolonged of vesicles, scaling and thickening of the skin.	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many of contact causing inflammation. Reply as observed in rats given oral doses ody surface area conversion) for 104 noted above) for 99 weeks. Reproduted (4.9-fold and 2.5-fole 1 mg/kg/day (0.5-fold the human diduring early embryonic development of the heart, a rare event, at an area conversion) and embryolethality ghout organogenesis. Meloxicam was noted above) throughout organogenesis. Melen. Mutagenicity: Meloxicam was not and an in vivo micronucleus test in ature search. Carcinogenicity Carcinogenicity	e to being oxidized in the air. They then form completed of the oxidation products are sensitisers. The seated or prolonged exposure to irritants may product a up to 0.8 mg/kg/day (approximately 0.4-fold the alweeks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dos at oral doses >/= 5 mg/kg/day (5.4-fold the human dos at oral doses of a following the seis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a mouse bone marrow. * Apotex SDS
POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER MELOXICAM WATER ETHANOL & POLYPROPYLENE/ POLYETHYLENE GLYCOL COPOLYMER Acute Toxicity	* Varies - dependent on degree of ethoxylation. Polyethers (such as ethoxylated surfactants and polyet mixtures of oxidation products. Animal testing reveals that whole the pure, non-oxidise oxidization products also cause irritation. The material may be irritating to the eye, with prolonge conjunctivitis. Carcinogenicity: No carcinogenic effect of meloxicam whuman dose at 15 mg/day for a 50 kg adult based on b mg/kg/day (approximately 2.2-fold the human dose, as female fertility in rats at oral doses up to 9 and 5 mg/kg increased incidence of embryolethality at oral doses >/dams were given meloxicam 2 weeks prior to mating a Meloxicam caused an increased incidence of septal de at 15 mg/day for a 50 kg adult based on body surface a dose, as noted above) when rabbits were treated throu mg/kg/day (approximately 2.2-fold the human dose, as observed when rats were given oral doses >/= 1 mg/kg adequate and well-controlled studies in pregnant wome chromosome aberration assay with human lymphocyte. No significant acute toxicological data identified in litera. The material may cause skin irritation after prolonged of vesicles, scaling and thickening of the skin.	thylene glycols) are highly susceptible of surfactant is non-sensitizing, many discontact causing inflammation. Repure sody surface area conversion) for 104 noted above) for 99 weeks. Reproductly day, respectively (4.9-fold and 2.5-fe 1 mg/kg/day (0.5-fold the human diduring early embryonic development of the heart, a rare event, at an earea conversion) and embryolethality aghout organogenesis. Meloxicam was not diduring throughout organogenesis. Meloxicam was not as and an in vivo micronucleus test in a future search. Carcinogenicity Reproductivity	e to being oxidized in the air. They then form complet of the oxidation products are sensitisers. The eated or prolonged exposure to irritants may product as up to 0.8 mg/kg/day (approximately 0.4-fold the weeks or in mice given oral doses up to 8.0 uctive Toxicity: Meloxicam did not impair male and old the human dose, as noted above). However, an ose, as noted above) was observed in rats when ent. Teratogenicity: Pregnancy Category C: oral dose of 60 mg/kg/day (64.5-fold the human dos at oral doses >/= 5 mg/kg/day (5.4-fold the human so not teratogenic in rats up to an oral dose of 4 esis. An increased incidence of stillbirths was oxicam crosses the placental barrier. There are no mutagenic in an Ames assay, or clastogenic in a mouse bone marrow. * Apotex SDS

Legend:

X − Data either not available or does not fill the criteria for classification
✓ − Data available to make classification

SECTION 12 Ecological information

Toxicity

t Test Duration (hr) Not Available	Species Not Available	Not Available	Source Not Available
Not Available	Not Available		
t Test Duration (hr)	Species	Value	Source
(x) 96h	Algae or other aquatic plants	<0.001mg/L	4
72h	Algae or other aquatic plants	275mg/l	2
	(x) 96h	Algae or other aquatic plants	Algae or other aquatic plants <0.001mg/L

Chemwatch: **5494-68** Page **9** of **11**

Version No: 2.1

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: **01/10/2021**Print Date: **05/10/2021**

	LC50	96h	Fish	>100mg/l	2
	EC50	48h	Crustacea	>79mg/L	4
	EC50	96h	Algae or other aquatic plants	<0.001mg/L	4
	Endpoint	Test Duration (hr)	Species	Value	Source
polypropylene/ polyethylene glycol copolymer	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
meloxicam	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
water	Not Available	Not Available	Not Available	Not Available	Not Available

Legend:

Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

For Ethanol: log Kow: -0.31 to -0.32; Koc 1: Estimated BCF= 3; Half-life (hr) air: 144; Half-life (hr) H2O surface water: 144; Henry's atm m3 /mol: 6.29E-06; BOD 5 if unstated: 0.93-1.67,63% COD: 1.99-2.11,97%; ThOD: 2.1.

Environmental Fate: Terrestrial - Ethanol quickly biodegrades in soil but may leach into ground water; most is lost by evaporation. Ethanol is expected to have very high mobility in soil. Volatilization of ethanol from moist soil surfaces is expected to be an important fate process. The potential for volatilization of ethanol from dry soil surfaces may exist. Biodegradation is expected to be an important fate process for ethanol based on half-lives on the order of a few days for ethanol in sandy soil/groundwater microcosms. Atmospheric Fate: Ethanol is expected to exist solely as a vapour in the ambient atmosphere. Vapour-phase ethanol is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals; the half-life for this reaction in air is estimated to be 5 days. Ethanol readily degraded by reaction with photochemically produced hydroxy radicals; release into air will result in photodegradation and wet deposition.

Aquatic Fate: When released into water ethanol readily evaporates and is biodegradable. Ethanol is not expected to adsorb to suspended solids and sediment. Volatilization from water surfaces is expected and volatilization half-lives for a model river and model lake are 3 and 39 days, respectively. Bioconcentration in aquatic organisms is considered to be low. Hydrolysis and photolysis in sunlit surface waters is not expected to be an important environmental fate process for ethanol and is unlikely to be persistent in aquatic environments.

For Surfactants: Kow cannot be easily determined due to hydrophilic/hydrophobic properties of the molecules in surfactants. BCF value: 1-350.

Aquatic Fate: Surfactants tend to accumulate at the interface of the air with water and are not extracted into one or the other liquid phases

Terrestrial Fate: Anionic surfactants are not appreciably sorbed by inorganic solids. Cationic surfactants are strongly sorbed by solids, particularly clays. Significant sorption of anionic and non-ionic surfactants has been observed in activated sludge and organic river sediments. Surfactants have been shown to improve water infiltration into soils with moderate to severe hydrophobic or water-repellent properties.

Ecotoxicity: Some surfactants are known to be toxic to animals, ecosystems and humans, and can increase the diffusion of other environmental contaminants. The acute aquatic toxicity generally is considered to be related to the effects of the surfactant properties on the organism and not to direct chemical toxicity. Surfactants should be considered to be toxic to aquatic species under conditions that allow contact of the chemicals with the organisms. Surfactants are expected to transfer slowly from water into the flesh of fish. During this process, readily biodegradable surfactants are expected to be metabolized rapidly during the process of bioaccumulation. Surfactants are not to be considered to show bioaccumulation potential if they are readily biodegradable.

DO NOT discharge into sewer or waterways

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
ethanol	LOW (Half-life = 2.17 days)	LOW (Half-life = 5.08 days)
water	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
ethanol	LOW (LogKOW = -0.31)

Mobility in soil

Ingredient	Mobility
ethanol	HIGH (KOC = 1)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- ► Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible.

Otherwis

• If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.

Where possible retain label warnings and SDS and observe all notices pertaining to the product.

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

ilium Meloxicam 40 Anti-Inflammatory Injection

Issue Date: 01/10/2021 Print Date: 05/10/2021

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- ► Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate

- DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- Recycle wherever possible or consult manufacturer for recycling options.
- Consult State Land Waste Authority for disposal.
- Bury or incinerate residue at an approved site.
- Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
ethanol	Not Available
polypropylene/ polyethylene glycol copolymer	Not Available
meloxicam	Not Available
water	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
ethanol	Not Available
polypropylene/ polyethylene glycol copolymer	Not Available
meloxicam	Not Available
water	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

ethanol is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

polypropylene/ polyethylene glycol copolymer is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

meloxicam is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) -Schedule 4

FEI Equine Prohibited Substances List - Controlled Medication

FEI Equine Prohibited Substances List (EPSL)

water is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (meloxicam)
Canada - DSL	No (meloxicam)
Canada - NDSL	No (ethanol; polypropylene/ polyethylene glycol copolymer; meloxicam; water)
China - IECSC	No (meloxicam)
Europe - EINEC / ELINCS / NLP	No (polypropylene/ polyethylene glycol copolymer; meloxicam)

Chemwatch: 5494-68 Page 11 of 11 Issue Date: 01/10/2021 Version No: 2.1 Print Date: 05/10/2021

ilium Meloxicam 40 Anti-Inflammatory Injection

National Inventory	Status
Japan - ENCS	No (meloxicam)
Korea - KECI	No (meloxicam)
New Zealand - NZIoC	Yes
Philippines - PICCS	No (meloxicam)
USA - TSCA	No (meloxicam)
Taiwan - TCSI	Yes
Mexico - INSQ	No (polypropylene/ polyethylene glycol copolymer)
Vietnam - NCI	Yes
Russia - FBEPH	No (meloxicam)
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

SECTION 16 Other information

Revision Date	01/10/2021
Initial Date	01/10/2021

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average

PC-STEL: Permissible Concentration-Short Term Exposure Limit

IARC: International Agency for Research on Cancer

ACGIH: American Conference of Governmental Industrial Hygienists

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit,

IDLH: Immediately Dangerous to Life or Health Concentrations

ES: Exposure Standard

OSF: Odour Safety Factor

NOAEL :No Observed Adverse Effect Level

LOAEL: Lowest Observed Adverse Effect Level

TLV: Threshold Limit Value LOD: Limit Of Detection

OTV: Odour Threshold Value

BCF: BioConcentration Factors

BEI: Biological Exposure Index

AIIC: Australian Inventory of Industrial Chemicals **DSL: Domestic Substances List**

NDSL: Non-Domestic Substances List

IECSC: Inventory of Existing Chemical Substance in China

EINECS: European INventory of Existing Commercial chemical Substances

ELINCS: European List of Notified Chemical Substances

NLP: No-Longer Polymers

ENCS: Existing and New Chemical Substances Inventory

KECI: Korea Existing Chemicals Inventory

NZIoC: New Zealand Inventory of Chemicals

PICCS: Philippine Inventory of Chemicals and Chemical Substances

TSCA: Toxic Substances Control Act

TCSI: Taiwan Chemical Substance Inventory

INSQ: Inventario Nacional de Sustancias Químicas

NCI: National Chemical Inventory

FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.